SCHEMBL4395818

SCHEMBL4395818

Cc1c(C(=O)O)noc1-c1ccco1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.50
PKM P14618 2/20 0.50
PTPN1 P18031 1/20 0.44
SMURF2 Q9HAU4 1/20 0.43
SMURF1 Q9HCE7 1/20 0.43
KMT2A Q03164 6/20 0.40
MEN1 O00255 5/20 0.40
MAPT P10636 4/20 0.40
POLB P06746 4/20 0.40
KDM4E B2RXH2 4/20 0.40
L3MBTL1 Q9Y468 4/20 0.40
TDP1 Q9NUW8 3/20 0.40
TSHR P16473 2/20 0.40
CTDSP1 Q9GZU7 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
PTGS1 P23219 1/20 0.40
PTGS2 P35354 1/20 0.40
RAB9A P51151 2/20 0.40
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4395634 0.82 ALDH1A1 (0.54) ALDH1A1PKMPTPN1KMT2AMEN1
SCHEMBL4076415 0.77 PTPN1 (0.67) ALDH1A1PTPN1SMURF2SMURF1KMT2A
SCHEMBL4395964 0.77 ALDH1A1 (0.45) ALDH1A1PKMPTPN1KMT2AMEN1
SCHEMBL5591183 0.72 IP6K1 (0.52) ALDH1A1PTPN1SMURF2SMURF1KMT2A
SCHEMBL28061414 0.72 ALDH1A1 (0.50) ALDH1A1PKMKMT2AMEN1MAPT
SCHEMBL569677 0.71 POLB (0.49) ALDH1A1PKMKMT2AMEN1MAPT
SCHEMBL7370615 0.71 ERCC1 (0.46) ALDH1A1PTPN1SMURF2SMURF1KMT2A
SCHEMBL22619715 0.71 PTPN1 (0.46) PKMPTPN1SMURF2SMURF1KMT2A
SCHEMBL5590836 0.71 IP6K1 (0.58) ALDH1A1PTPN1SMURF2SMURF1KDM4E
SCHEMBL31039807 0.71 PTPN1 (0.46) PKMPTPN1SMURF2SMURF1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP claimed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US claimed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP claimed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO claimed
EP-1971600-B1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK BIOPHARMACEUTICALS CO LTD (KR) 2013-08-21 EP disclosed
US-20090131336-A1 Isoxazole Derivatives and Use Thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2009-05-21 US disclosed
EP-1971600-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK Holdings Co., Ltd. (KR) 2008-09-24 EP disclosed
WO-2007078113-A1 ISOXAZOLE DERIVATIVES AND USE THEREOF SK HOLDINGS CO., LTD. (KR) 2007-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131336-A1 Isoxazole Derivatives and Use Thereof WNT3A, WNT1, WNT3 ALDH1A1 706/4885PKM 2602/4885PTPN1 2026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.